dr. Julia Newton
foto: © Regina Clos
Volgens de kop van
een artikel op de voorpagina van de Telegraph
n.a.v. onderstaande studie
kan 1/3 van de ME-patiŽnten behandeld worden omdat ze eigenlijk
POTS-patiŽnten zouden zijn.
Voor een tekstuele versie van het artikel in de Telegraph, klik op onderstaande logo:
Lijkt me een wat simpele redenering, aangezien ME/CVS
orthostatische intolerantie niet uitsluit.
Overigens ging het in deze studie niet om een vergelijking met
ME- maar met
Voor het persbericht bij deze studie, klik op onderstaande afbeelding:
Postural tachycardia syndrome is associated with significant symptoms
and functional impairment predominantly affecting young women: a UK perspective.
BMJ Open 2014;4:e004127 doi:10.1136/bmjopen-2013-004127.
McDonald C, Koshi S, Busner L, Newton JL.
Received 27 September 2013
Accepted 11 October 2013
Published 16 June 2014
To examine a large UK cohort of patients with postural tachycardia syndrome (PoTS),
to compare demographic characteristics, symptoms and treatment of PoTS
at one centre compared to the largest patient group PoTS UK and
to verify if their functional limitation is similar to patients with chronic fatigue syndrome (CFS).
A cross-sectional study assessed
the frequency of symptoms and their associated variables.
Patients and setting
Two PoTS cohorts were:
recruited via PoTS UK,
diagnosed at Newcastle Hospitals National Health Service (NHS) Foundation Trust 2009Ė2012.
Patients with PoTS
were then compared to a matched cohort with CFS.
Main outcome measures
demographics, time to diagnosis, education, disability, medications, comorbidity and precipitants.
Symptom assessment tools captured,
Fatigue Impact Scale, Epworth Sleepiness Scale, Orthostatic Grading Scale (OGS),
Hospital Anxiety and Depression Scale, Health Assessment Questionnaire,
Cognitive Failures Questionnaire.
136 patients with PoTS participated (84 members of PoTS UK (170 cohort; 50% return) and
52 (87 cohort; 60%) from Newcastle Clinics).
The PoTS UK population
was significantly younger than the clinic patients,
with significantly fewer men (p=0.005).
Over 60% had a university or postgraduate degree.
Significantly more of the PoTS UK cohort were working,
with hours worked being significantly higher (p=0.001).
Time to diagnosis was significantly longer in the PoTS UK cohort (p=0.04).
Symptom severity was comparable between cohorts.
The PoTS total group was compared with a matched CFS cohort;
despite comparable levels of fatigue and sleepiness,
autonomic symptom burden (OGS) was statistically significantly higher.
The most common treatment regime included β-blockers.
Overall, 21 treatment combinations were described.
Up to 1/3 were taking no treatment.
Patients with PoTS are predominantly women, young, well-educated and
have significant and debilitating symptoms that impact significantly on quality of life.
Despite this, there is no consistent treatment.